◀ Back to BCL2

BCL2 — CDK5

Text-mined interactions from Literome

Pathan et al., Neoplasia (New York, N.Y.) 2001 : Comparison of a variety of pharmacological inhibitors of serine/threonine-specific protein kinases demonstrated that the cyclin dependent kinase inhibitor, flavopiridol, selectively blocks Bcl-2 phosphorylation induced by antimicrotubule drugs
Pathan et al., Neoplasia (New York, N.Y.) 2001 : Comparison of a variety of pharmacological inhibitors of serine/threonine-specific protein kinases demonstrated that the cyclin dependent kinase inhibitor, flavopiridol, selectively blocks Bcl-2 phosphorylation induced by antimicrotubule drugs
Wang et al., Cell Death Differ 2006 : Inhibition of Cdk5 inhibits PI3K/Akt and ERK phosphorylation and Bcl-2 expression, and thus sensitizes the differentiated cells to DNA-damage
Cheung et al., J Neurosci 2008 : We found that Cdk5 mediated phosphorylation of Bcl-2 at Ser70 was required for the neuroprotective effect of Bcl-2 ... Our observations revealed that Cdk5 mediated Bcl-2 phosphorylation is pivotal for the antiapoptotic effect of Bcl-2 and contributes to the maintenance of neuronal survival by Cdk5
Huang et al., J Biochem 2009 : In addition, the inhibition of Cdk5 prevented Bcl-2 phosphorylation and enhanced H ( 2 ) O ( 2 ) -induced caspase-3 activation as well as subsequent DNA fragmentation ... Taken together, these results provide evidence for another cytoprotective role of EGF in that it is mediated through its stimulation of nestin expression which leads to the prevention of caspase activation by Cdk-5 induced Bcl-2 phosphorylation in rat VSMCs
Veliz et al., Cancer Control 2012 (Leukemia, Lymphocytic, Chronic, B-Cell...) : These investigational agents include rituximab, alemtuzumab, ofatumumab, bendamustine, high-dose methylprednisolone, lenalidomide, lumiliximab, cyclin dependent kinase inhibitors, small modular immunopharmaceuticals, Bcl-2 inhibitors , and histone deacetylase inhibitors